<DOC>
	<DOCNO>NCT01153321</DOCNO>
	<brief_summary>The purpose study find AZD2423 reduce inflammation lung patient mild COPD .</brief_summary>
	<brief_title>Investigation Effect Oral Treatment With 100 mg AZD2423 Subjects With Mild Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Only woman nonchild bear potential include study i.e . woman permanently surgically sterilise post menopausal . ≥ 40 year age Visit 1 Clinical diagnosis COPD ( GOLD stage 1 ) FEV1 ≥ 80 % predict normal postbronchodilator Visit 1 ( GOLD stage 1 ) FEV1/FVC &lt; 70 % postbronchodilator Visit 1 ( GOLD stage 1 ) Any clinically significant disease disorder , opinion Investigator , may either put subject risk influence way drug work Any clinically relevant abnormal finding physical examination , blood urine test result , vital sign ECG Visit 1 may put subject risk study , affect ability take part influence result study A past history current indication renal ( kidney ) failure Subjects risk active tuberculosis disease reactivation Subjects clinically significant illness within 4 week Visit 2 ( start treatment )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Respiratory disease</keyword>
	<keyword>chronic obstructive pulmonary disease</keyword>
</DOC>